|Table of Contents|

Influence of Phe112,Trp86 and Tyr108 on binding and chemotaxis effects of CCR5 to chemokine CCL5

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 04
Page:
591-597
Research Field:
Publishing date:

Info

Title:
Influence of Phe112,Trp86 and Tyr108 on binding and chemotaxis effects of CCR5 to chemokine CCL5
Author(s):
SONG Xiaoxu; CHEN Ling; YU Jing
School of Life Sciences and Biotechnology,Shanghai Jiao Tong University,Shanghai 200240,China.
Keywords:
CCR5; CCL5; site-directed mutagenesis; tumor growth; tumor invasion
PACS:
R73-3
DOI:
10.3969/j.issn.1672-4992.2023.04.001
Abstract:
Objective:To reveal the key amino acids of human C-C chemokine receptor 5 (hCCR5) for binding to human C-C motif chemokine ligand 5 (hCCL5)and the related chemotaxis effects.Methods:According to the information suggested by bioinformatics analysis,site-directed mutagenesis technique was used to construct mutant plasmids CCR5-F112A,CCR5-W86A and CCR5-Y108A for Phe112,Trp86 and Tyr108 in CCR5,and human embryonic kidney cells HEK293T were infected with such mutants by lentivirus infection to obtain CCR5-F112A,CCR5-W86A and CCR5-Y108A mutants.The binding effects of CCR5-F112A,CCR5-W86A and CCR5-Y108A mutants with CCL5 were further detected by laser scanning confocal microscopy.In addition,the effects of these mutations on tumor proliferation and invasion were also evaluated by CCK8 and Transwell invasion experiments.Results:The experimental results showed that after the mutation of Phe112 or Trp86 in CCR5,the binding ability of CCR5 receptor to CCL5 and the chemotaxis of CCL5 were significantly reduced,but Tyr108 was not significant.Conclusion:Phe112 and Trp86 in CCR5 are the key amino acids for the binding of CCR5 to CCL5,and the construction of these mutants also provides an experimental tool for further elucidating the biological roles of the CCL5/CCR5 axis on tumor progression.

References:

[1] ALDINUCCI D,BORGHESE C,CASAGRANDE N.The CCL5/CCR5 axis in cancer progression［J］.Cancers (Basel),2020,12(7):1765.
[2] MIAO M,DE CLERCQ E,LI G.Clinical significance of chemokine receptor antagonists［J］.Expert Opin Drug Metab Toxicol,2020,16(1):11-30.
[3] CASAGRANDE N,BORGHESE C,VISSER L,et al.CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth［J］.Haematologica,2019,104(3):564-375.
[4] BAN Y,MAI J,LI X,et al.Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity［J］.Cancer Res,2017,77(11):2857-2868.
[5] GAO LF,ZHONG Y,LONG T,et al.Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling［J］.J Exp Clin Cancer Res,2022,41(1):81.
[6] WU YC,SHEN YC,CHANG JW,et al.Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro［J］.Cytokine,2018,110:94-103.
[7] LIU J,WANG C,MA X,et al.High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFbeta1［J］.J Pathol,2019,247(4):481-493.
[8] SINGH SK,MISHRA MK,ELTOUM IA,et al.CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells［J］.Sci Rep,2018,8(1):1323.
[9] VADAY GG,PEEHL DM,KADAM PA,et al.Expression of CCL5 (RANTES) and CCR5 in prostate cancer［J］.Prostate,2006,66(2):124-134.
[10] ZI J,YUAN S,QIAO J,et al.Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells［J］.Am J Cancer Res,2017,7(4):869-880.
[11] CASAGRANDE N,BORGHESE C,ALDINUCCI D.In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes,enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability［J］.Haematologica,2022,107(1):287-291.
[12] MENU E,DE LEENHEER E,DE RAEVE H,et al.Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions:a study in the 5TMM model［J］.Clin Exp Metastasis,2006,23(5-6):291-300.
[13] LECHNER J,SCHULZ T,LEJEUNE B,et al.Jawbone cavitation expressed RANTES/CCL5:case studies linking silent inflammation in the jawbone with epistemology of breast cancer［J］.Breast Cancer (Dove Med Press),2021,13:225-240.
[14] LI M,SUN X,ZHAO J,et al.CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization［J］.Cell Mol Immunol,2020,17(7):753-764.
[15] JIAO X,NAWAB O,PATEL T,et al.Recent advances targeting CCR5 for cancer and its role in immuno-oncology［J］.Cancer Res,2019,79(19):4801-4807.
[16] SUENAGA M,STINTZING S,CAO S,et al.Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer:analysis of the FIRE-3 trial［J］.Eur J Cancer,2019,107:100-114.
[17] BULE P,AGUIAR SI,AIRES-DA-SILVA F,et al.Chemokine-directed tumor microenvironment modulation in cancer immunotherapy［J］.Int J Mol Sci,2021,22(18):9804.
[18] HUSSAIN S,PENG B,CHERIAN M,et al.The roles of stroma-derived chemokine in different stages of cancer metastases［J］.Front Immunol,2020,11:598532.
[19] LIU H,YANG Z,LU W,et al.Chemokines and chemokine receptors:A new strategy for breast cancer therapy［J］.Cancer Med,2020,9(11):3786-3799.
[20] KITAMURA T,POLLARD JW.Therapeutic potential of chemokine signal inhibition for metastatic breast cancer［J］.Pharmacol Res,2015,100:266-270.
[21] TAN C,HU W,HE Y,et al.Cytokine-mediated therapeutic resistance in breast cancer［J］.Cytokine,2018,108:151-159.
[22] CHUNG CW,COOKE RM,PROUDFOOT AE,et al.The three-dimensional solution structure of RANTES［J］.Biochemistry,1995,34(29):9307-9314.
[23] WANG X,WATSON C,SHARP JS,et al.Oligomeric structure of the chemokine CCL5/RANTES from NMR,MS,and SAXS data［J］.Structure,2011,19(8):1138-1148.
[24] HUANG B,WANG H,ZHENG Y,et al.Structure-based design and development of chemical probes targeting putative MOR-CCR5 heterodimers to inhibit opioid exacerbated HIV-1 infectivity［J］.J Med Chem,2021,64(11):7702-7723.
[25] TAMAMIS P,FLOUDAS CA.Elucidating a key anti-HIV-1 and cancer-associated axis:the structure of CCL5 (Rantes) in complex with CCR5［J］.Sci Rep,2014,4:5447.

Memo

Memo:
National Natural Science Foundation of China(No.32071298）；国家自然科学基金面上项目（编号：32071298）
Last Update: 1900-01-01